



SunVax LNPs demonstrated performance comparable to, and in some cases exceeding, that of the leading commercial LNPs. Six- to eight-week-old Balb/c mice (n=5 per group) were intramuscularly injected with 1 µg SunVax's self-amplifying mRNA encoding with Luciferase, formulated with either SunVax LNPs (SV1, SV2, SV3) or benchmark LNPs (Moderna SM102, BioNTech ALC0315, Alnylam MC3). Bioluminescence intensity (Y-axis) was measured over time (X-axis, days post-injection) to assess *in vivo* expression levels.